novo nordisk semaglutide clinical trials FLOW Trial (funded by Nordisk): showed 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators Novo Nordisk has officially filed
Description
Initially developed as a treatment for type 2 diabetes, the drug gained widespread attention after clinical trials showed it reduced baseline body weight by approximately 10 percent to 15 percent
It works through specific actions in the body that support weight loss and improve metabolic health
Meet with your doctor via video to review health history and goals
20 Nonetheless, headache occurring during GLP-1 RA therapy may not be directly drug-induced, as secondary factors like dehydration and hypoglycemia may contribute
